Bruker's $66.54 close tops its September 30 peak by 2.76%, a new high for the stock, with the rest of the toolmaker group higher alongside it.
Moves: Nov 9, 2026 · Alpha Vantage daily close
13 more related stocks · 3 have no US listing
Headquartered in Billerica, MA Fiscal year ends December NASDAQ: BRKR bruker.com
Bruker Corporation (Nasdaq: BRKR) develops and sells high-performance scientific instruments and analytical and diagnostic solutions. Its tools let scientists and engineers study life and materials at molecular, cellular and microscopic levels.
The company serves several markets:
- post-genomic life science research in molecular and cell biology
- specialty diagnostics
- applied and biopharma applications
- microscopy and nanoanalysis
- industrial and cleantech research
- next-generation semiconductor metrology supporting AI
Its product portfolio covers:
- preclinical imaging
- clinical phenomics research
- proteomics and multiomics
- spatial and single-cell biology
- functional, structural and condensate biology
- clinical microbiology and molecular diagnostics
- semiconductor industry solutions
Effective July 1, 2026, Bruker reorganized into four reportable segments. Three sit under the Bruker Scientific Instruments (BSI) umbrella: BSI Biosystems (BIOS), BSI Microbiology and Infection Diagnostics (BMID) and BSI NANO. The fourth is Bruker Energy & Supercon Technologies (BEST), which focuses on superconductor and energy technologies.
Revenue is diversified across Europe, the United States, Asia Pacific and other regions. Customers include academic and government research institutions, biopharma companies, clinical microbiology labs and industrial and semiconductor firms.
Bruker supplements organic growth with acquisitions. It has a Series A Mandatory Convertible Preferred Stock outstanding. Updated
Bruker's $66.54 close tops its September 30 peak by 2.76%, a new high for the stock, with the rest of the toolmaker group higher alongside it.
Moves: Nov 9, 2026 · Alpha Vantage daily close
13 more related stocks · 3 have no US listing
Duolingo closed up 26.8% at $162.31, the biggest move in a 383-stock priority universe that saw double-digit swings on both ends. Datadog, Vertiv, CVS and Quanta all gave up more than 12% in the same session.
The selloff landed the same day Bruker filed its Q3 2026 earnings release, erasing roughly $800 million from a life science tools name. Moves this size are rare here, and the selling held into the close.
Cost discipline pushed non-GAAP operating margin up 400 basis points to 16.3%, beating expectations even as a goodwill impairment dragged GAAP results to a loss. Management reaffirmed full-year non-GAAP EPS guidance and pointed to double-digit EPS growth in FY27 behind a fifth straight quarter of book-to-bill above one.
In the third quarter, we achieved very significant margin expansion and non-GAAP EPS growth, driven by our focus on cost discipline and execution. Bruker's positive booking trends continued with the fifth consecutive quarter of Bruker Scientific Instruments (BSI) book-to-bill greater than one.
Five straight quarters of orders outpacing shipments at the scientific instruments arm means the $8.6 billion lab-tools maker is building backlog while cost cuts do the heavy lifting on earnings. That combination is what investors in the group have been waiting to see.
We see strengthening demand in most of our end markets, and in Q3 also in the US academic market. With BSI organic bookings and backlog both up mid-single digits % year-to-date, we expect revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27.
The US academic market, the biggest overhang on lab tool makers all year, turned in the quarter, and Laukien is now underwriting double-digit EPS growth for FY27 off it. At an $8.6 billion market cap, that guidance is the whole thesis for Bruker.
Bruker closed at $64.51, a fresh 52-week high that edges 0.26% past the July 30 peak and nearly doubles its March low near $32.71. The $9.8 billion name now has a clean new level for traders to defend.
Arm's 8.5% slide was the deepest move in a 111-stock priority list at Wednesday's close, with Bruker leading the upside at 7.5%.
A 9.6% intraday jump adds close to a billion dollars of market value to a $9.9 billion company in a single session. Moves this size are rare for a life sciences tools name, so watch whether the gain holds into the close.
Bruker holds its nickel quarterly payout for a 10th straight year, unchanged from a year ago. At 0.41%, the yield is a token of consistency rather than income, so the instruments business is the reason to own it.
Pre-Market Stock Futures: The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA | NVDA Price Prediction) blew out its fiscal third-quarter results and offered strong forward guidance, though perhaps not as…
Bruker Corporation (NASDAQ: BRKR | BRKR Price Prediction) delivered a sharp earnings beat this morning, lifting shares nearly 7% despite underlying headwinds that reveal a company in transition. Non-GAAP EPS of $0.45…
Here is an assessment of how safe the dividend at Abbott Laboratories appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Wednesday’s top analyst upgrades and downgrades included Alliance Data, AvalonBay, Boston Properties, Bruker, Camden Properties and CBRE.
Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Boston Beer, Carvana, HD Supply, Marathon Petroleum, Square, Trade Desk and Whirlpool.
The top analyst upgrades, downgrades and initiations seen on Thursday include Advanced Micro Devices, Caterpillar, NRG Energy, Nvidia, Procter & Gamble, Square, Red Hat, Transocean, Viacom and Wisdom Tree.
The top analyst upgrades, downgrades and other research calls from Friday include Activision, Aetna, Apple, Blue Apron, Pandora, Starbucks, Twitter and YogaWorks.
The top analyst upgrades, downgrades and other research calls from Thursday include Agilent Technologies, AT&T, Halcon Resources, HP, International Paper, Seagate technology and Snap.
Over the past five, 10 and 20 years, the life science and bioproduction segments have tended to outperform the S&P 500 more often than not.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Biogen, Discovery Communications, Mosaic, Plains All American, Phillips 66 and Rubicon Project.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Dick's Sporting Goods, Randgold Resources, Royal Dutch Shell, Sysco and Tesla Motors.
Tuesday’s top analyst upgrades, downgrades and initiations include AT&T, Capital One, Cisco, Novartis, Sprint and Starbucks.
The top analyst calls for Thursday include Celgene, DigitalGlobe, Micron Technology, Paychex and Bed Bath & Beyond.
The major money management firms that run exchange traded funds have to do regular quarterly rebalances to reset their portfolios to the proper allocation levels.
ThinkstockThe second-quarter earnings parade may be winding down as we hit August, but the number of companies meeting or exceeding expectations for the period continues to grow. The equity research team at…
Bruker Corporation (Nasdaq: BRKR) develops and sells high-performance scientific instruments and analytical and diagnostic solutions. Its tools let scientists and engineers study life and materials at molecular, cellular and microscopic levels.
24/7 Wall St.'s 12-month price target for BRKR is $73.39, rated Buy. The Wall Street consensus target is $68.00. BRKR price prediction →